

ASX RELEASE

Ellex Medical Lasers Limited (ASX:ELX)

Adelaide, Australia

Date: 11 July 2018

Release: Immediate

Topic: Ellex Announces Appointment of President, Ellex iTrack™



Adelaide, Australia, 11 July 2018 – Ellex Medical Lasers Limited (ASX:ELX), a global leader in medical devices for the diagnosis and treatment of eye disease, today announced the appointment of Mr. Joaquin Wolff to the position of President, Ellex iTrack™.

In this newly created position Mr. Wolff expands the Company's executive management team and will be dedicated to managing the Ellex iTrack™ business in the rapidly growing minimally invasive glaucoma surgery (MIGS) device market. He will be based out of Ellex iTrack™ headquarters in Fremont in the San Francisco Bay area.

Mr. Wolff is a recognized expert in the ophthalmic medical device industry with over 25 years of executive leadership experience. He has held senior management positions in industry-leading companies, including Novartis (Alcon) and Johnson & Johnson (VISX /AMO). In these roles he was responsible for spearheading the launch of several new product platforms in the USA, which attained top market share positions.

Most recently, Mr. Wolff served as a senior commercialization strategist for a health market consultants consortium of senior-level industry experts working with emerging and early stage start up companies in the Silicon Valley. He was responsible for developing global commercialization execution strategies targeted at the MIGS market.

Ellex CEO Tom Spurling said, "Joaquin brings a wealth of experience and a proven track record of successful commercial product launches in the USA across many specialty segments within the ophthalmic industry. Furthermore, that experience extends across early-stage growth companies and large organizations, including direct exposure in the specialist MIGS market. We are excited to have his blue-chip credentials, which we believe will add immediate value to the existing Ellex iTrack™ team. We see his appointment as a major step forward in the growth of our business, which is capitalizing on the growing shift toward MIGS in the treatment of glaucoma."

ABOUT ELLEX iTRACK™ and ABiC™

ABiC™ is a comprehensive MIGS procedure that utilizes Ellex's proprietary iTrack™ illuminated microcatheter to circumferentially viscodilate Schlemm's canal and the trabecular meshwork to reduce intraocular pressure (IOP) and or to reduce patients' dependence on medications. Unlike other MIGS procedures, it restores natural aqueous outflow without damaging ocular tissue or leaving behind a foreign body, such as a stent or shunt.

A key challenge in the management of glaucoma is that the point(s) of outflow resistance is not always known. Whereas other MIGS procedures treat only one aspect of aqueous outflow, and thereby may not treat the areas of blockage, ABiC™ with iTrack™ comprehensively accesses, catheterizes, and viscodilates the trabecular meshwork, Schlemm's canal, and importantly, the distal outflow system, beginning with the collector channels, thus eliminating the guesswork inherent in stent-based MIGS.

ABiC™ with iTrack™ has been shown to be effective as both a stand-alone procedure and as a combined procedure performed in conjunction with cataract surgery.

For additional information on ABiC™ with iTrack™ please visit www.glaucoma-iTrack.com

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative products that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Fremont, Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling, CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Mark Lindh
W +61 8 8232 8800 | M +61 414 551 361
mlindh@ellex.com

Maria Maieli, CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes, SA, 5095
W +61 8 7074 8200
mmaieli@ellex.com